http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 20 May 2024 16:06:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++MERRIMACK+PHARMACEUTICAL+++++++++++++/23252226.html si-local-file:///var/storage/secattach/20240520/23252226.html http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++MERRIMACK+PHARMACEUTICAL+++++++++++++/23252226.html Mon, 20 May 2024 16:06:00 -0400 MACK O.00647906 http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++MERRIMACK+PHARMACEUTICAL+++++++++++++/23252226.html si-local-file:///var/storage/secattach/20240520/23252226.html http://www.streetinsider.com/SEC+Filings/Form++15-12G+++++MERRIMACK+PHARMACEUTICAL+++++++++++++/23252226.html Mon, 20 May 2024 16:06:00 -0400 MACK O.00647906 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++MERRIMACK+PHARMACEUTICAL++For%3A+Mar+31/23234025.html si-local-file:///var/storage/secattach/20240515/23234025.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++MERRIMACK+PHARMACEUTICAL++For%3A+Mar+31/23234025.html Wed, 15 May 2024 16:30:00 -0400 MACK O.00647906 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++MERRIMACK+PHARMACEUTICAL++For%3A+Mar+31/23234025.html si-local-file:///var/storage/secattach/20240515/23234025.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++MERRIMACK+PHARMACEUTICAL++For%3A+Mar+31/23234025.html Wed, 15 May 2024 16:30:00 -0400 MACK O.00647906 http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Press+Releases/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html <p><strong>STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 /</strong> Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.</p><p>Hans Schikan has been a member of the Board since 2018 and is a http://www.streetinsider.com/Accesswire/Vicore+Expands+and+Strengthens+its+Board+of+Directors/23218417.html Tue, 14 May 2024 02:20:00 -0400 KRON MACK MXCT NTGN PHVS RNA TBIO VECT http://www.streetinsider.com/SEC+Filings/Form++25+++++++++MERRIMACK+PHARMACEUTICAL+++++++++++++/23209810.html si-local-file:///var/storage/secattach/20240510/23209810.html http://www.streetinsider.com/SEC+Filings/Form++25+++++++++MERRIMACK+PHARMACEUTICAL+++++++++++++/23209810.html Fri, 10 May 2024 16:46:00 -0400 MACK O.00647906 http://www.streetinsider.com/SEC+Filings/Form++25+++++++++MERRIMACK+PHARMACEUTICAL+++++++++++++/23209810.html si-local-file:///var/storage/secattach/20240510/23209810.html http://www.streetinsider.com/SEC+Filings/Form++25+++++++++MERRIMACK+PHARMACEUTICAL+++++++++++++/23209810.html Fri, 10 May 2024 16:46:00 -0400 MACK O.00647906 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MERRIMACK+PHARMACEUTICAL++For%3A+May+10/23209756.html si-local-file:///var/storage/secattach/20240510/23209756.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MERRIMACK+PHARMACEUTICAL++For%3A+May+10/23209756.html Fri, 10 May 2024 16:43:00 -0400 MACK O.00647906 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MERRIMACK+PHARMACEUTICAL++For%3A+May+10/23209756.html si-local-file:///var/storage/secattach/20240510/23209756.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MERRIMACK+PHARMACEUTICAL++For%3A+May+10/23209756.html Fri, 10 May 2024 16:43:00 -0400 MACK O.00647906 http://www.streetinsider.com/Press+Releases/Merrimack+Pharmaceuticals%2C+Inc.+Announces+Stockholder+Approval+of+Plan+of+Dissolution+And+Cash+Liquidating+Dividend+Amount+of+%2415.10+Per+Share+of+Common+Stock/23209491.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of Directors declared a liquidating cash dividend in the amount of $15.10 per share. The dividend is expected to be paid on or about May 17, 2024. Merrimack’s Common Stock will trade on NASDAQ through May 17, 2024 and will delist from NASDAQ on May 20, 2024. </p><p> “We appreciate shareholder support for the plan of dissolution and the opportunity to fulfill our commitment to http://www.streetinsider.com/Press+Releases/Merrimack+Pharmaceuticals%2C+Inc.+Announces+Stockholder+Approval+of+Plan+of+Dissolution+And+Cash+Liquidating+Dividend+Amount+of+%2415.10+Per+Share+of+Common+Stock/23209491.html Fri, 10 May 2024 16:30:00 -0400 A.06822034 MACK O.00647906 O.20026344